Möchten Sie immer auf dem neuesten Stand bleiben?

Oslo, Norway, October 2, 2015: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, today announces that the first patient has...

Oslo, September 22, 2015 - Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology today announces that a new patent for Cevira has...

Reference is made to the announcement on 8 September 2015 in respect of a capital increase of 50 830 new shares following exercise of employee share options in the company. The share capital...

The board of directors of Photocure ASA has resolved a share capital increase pursuant to employees exercising vested options granted under the company's employee incentive scheme. The company's...

Oslo, Norway, 4 September,  2015: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces that its partner and...

Kjetil Hestdal, President and Chief Executive Officer will present a Photocure company overview at the Pareto Securities' 6th Annual Health Care Seminar in Stockholm, on Friday, August 28, 2015 at...

Oslo, Norway, 19 August, 2015: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies, announces today the appointment of BioSyent Pharma Inc. as their...

Oslo, Norway, 13 August 2015: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies, announces its results for the second quarter and the first half...

Oslo, Norway, 10 August, 2015: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today the approval of the Special...

This is a correction of the announcement from 13:12 06.08.2015. Reason for the correction: Corrected day for presentation to Thursday 13 August 2015. Photocure will present its second quarter and...